Posts Tagged ‘non-small cell lung cancer (NSCLC)’:

Novel specific therapeutics: inhibitors of MDM2, ALK and PARP

Yuan, Y ; Liao, YM ; Hsueh, CT ; Mirshahidi, HR “JOURNAL OF HEMATOLOGY & ONCOLOGY 2011 Apr” We reviewed preclinical data and clinical development of MDM2 (murine double minute 2), ALK (anaplastic lymphoma kinase) and PARP (poly [ADP-ribose] polymerase) inhibitors. MDM2 binds to p53, and promotes degradation of p53 through ubiquitin-proteasome degradation. JNJ-26854165 and

(Read More…)

© Apoptosis|apoptosis inhibitor|apoptosis pathway
CyberChimps